Multidrug Resistance in Acute Myeloid Leukemia

Maria R. Baer(University of Maryland, Baltimore), C. D. Bloomfield

JNCI Journal of the National Cancer Institute

May 15, 1991

10.1093/jnci/83.10.663

Cited by 38

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

|New England Journal of Medicine|2019|1.3k

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

|The Lancet|2021|795

<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

|Journal of Clinical Oncology|2010|764

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

|The Lancet Oncology|2017|493

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

|Journal of Clinical Oncology|2012|408